In a note out Monday morning, Harrison issued a rare double upgrade on Biogen (ticker: BIIB), raising his rating to Overweight from Underweight, and increasing his price target by $94 to $357.“While BIIB remains... It’s time to take a gamble on Biogen stock, according to Morgan Stanley analyst Matthew Harrison.